VM 201

Drug Profile

VM 201

Latest Information Update: 19 Jun 2001

Price : $50

At a glance

  • Originator Columbia University
  • Class Anticoagulants; Antithrombotics; Blood coagulation factors
  • Mechanism of Action Factor IXa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Blood coagulation disorders; Stroke; Thrombosis

Most Recent Events

  • 19 Jun 2001 Discontinued - Preclinical for Thrombosis in USA (IV)
  • 19 Jun 2001 Discontinued - Preclinical for Stroke in USA (IV)
  • 19 Jun 2001 Discontinued - Preclinical for Coagulation disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top